aTYR PHARMA INC Earnings Per Share, Basic and Diluted
aTYR PHARMA INC (ATYR) reported Earnings Per Share, Basic and Diluted of -$0.44 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- aTYR PHARMA INC earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.44.
- aTYR PHARMA INC earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.42.
- aTYR PHARMA INC earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.64.
- aTYR PHARMA INC earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.51.
- aTYR PHARMA INC earnings per share, basic and diluted for fiscal 2021 was -$1.77.
- aTYR PHARMA INC earnings per share, basic and diluted for fiscal 2020 was -$1.77.
- aTYR PHARMA INC earnings per share, basic and diluted for fiscal 2019 was -$7.03.
- aTYR PHARMA INC earnings per share, basic and diluted for fiscal 2018 was -$16.11.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 6 month as first filed | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month | Earnings Per Share, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | -$0.44 10-Q · filed 2022-05-10 | |||||||
| 2021-12-31 | -$1.77 10-K · filed 2022-03-15 | |||||||
| 2021-09-30 | -$0.42 10-Q · filed 2021-11-12 | -$1.56 10-Q · filed 2021-11-12 | ||||||
| 2021-06-30 | -$0.64 10-Q · filed 2021-08-11 | -$1.16 10-Q · filed 2021-08-11 | ||||||
| 2021-03-31 | -$0.51 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | -$1.77 10-K · filed 2022-03-15 | |||||||
| 2020-09-30 | -$0.68 10-Q · filed 2021-11-12 | -$1.31 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | -$0.69 10-Q · filed 2021-08-11 | -$0.58 10-Q · filed 2021-08-11 | ||||||
| 2019-12-31 | -$1.54 10-K · filed 2020-03-26 | -$7.03 10-K · filed 2022-03-15 | ||||||
| 2019-09-30 | -$1.47 10-Q · filed 2020-11-13 | -$5.55 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | -$1.80 10-Q · filed 2020-08-13 | -$4.23 10-Q · filed 2020-08-13 | ||||||
| 2019-03-31 | -$2.54 10-K · filed 2020-03-26 | -$0.18 10-Q · filed 2019-05-14 | ||||||
| 2018-12-31 | -$2.92 10-K · filed 2020-03-26 | -$0.21 10-K · filed 2019-03-26 | -$16.11 10-K · filed 2021-03-24 | -$1.15 10-K · filed 2019-03-26 | ||||
| 2018-09-30 | -$3.33 10-K · filed 2020-03-26 | -$0.24 10-Q · filed 2018-11-14 | -$13.22 10-Q · filed 2019-11-14 | -$0.95 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | -$4.88 10-K · filed 2020-03-26 | -$0.35 10-Q · filed 2018-08-14 | -$9.89 10-Q · filed 2019-08-14 | -$0.71 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | -$5.01 10-K · filed 2020-03-26 | -$0.36 10-Q · filed 2018-05-15 | ||||||
| 2017-12-31 | -$0.39 10-K · filed 2019-03-26 | -$26.13 10-K · filed 2020-03-26 | -$1.87 10-K · filed 2018-03-20 | |||||
| 2017-09-30 | -$0.43 10-K · filed 2019-03-26 | -$1.50 10-Q · filed 2018-11-14 | ||||||
| 2017-06-30 | -$0.51 10-K · filed 2019-03-26 | -$1.07 10-Q · filed 2018-08-14 | ||||||
| 2017-03-31 | -$0.56 10-K · filed 2019-03-26 | |||||||
| 2016-12-31 | -$0.53 10-K · filed 2018-03-20 | -$1.11 derived: net income ÷ weighted average shares · filed 2019-03-26 | -$1.76 derived: net income ÷ weighted average shares · filed 2019-03-26 | -$2.44 10-K · filed 2019-03-26 | ||||
| 2016-09-30 | -$0.58 10-K · filed 2018-03-20 | -$1.23 derived: net income ÷ weighted average shares · filed 2017-11-14 | -$1.91 10-Q · filed 2017-11-14 | |||||
| 2016-06-30 | -$0.65 10-K · filed 2018-03-20 | -$1.33 10-Q · filed 2017-08-14 | ||||||
| 2016-03-31 | -$0.68 10-K · filed 2018-03-20 | |||||||
| 2015-12-31 | -$0.70 10-K · filed 2017-03-16 | -$1.18 derived: net income ÷ weighted average shares · filed 2018-03-20 | -$1.88 derived: net income ÷ weighted average shares · filed 2018-03-20 | -$3.03 10-K · filed 2018-03-20 | ||||
| 2015-09-30 | -$0.48 10-K · filed 2017-03-16 | -$1.17 derived: net income ÷ weighted average shares · filed 2016-11-14 | -$2.38 10-Q · filed 2016-11-14 | -$3.72 derived: net income ÷ weighted average shares · filed 2017-03-16 | ||||
| 2015-06-30 | -$0.74 10-K · filed 2017-03-16 | -$2.53 10-Q · filed 2016-08-10 | -$4.70 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$7.50 derived: net income ÷ weighted average shares · filed 2017-03-16 | ||||
| 2015-03-31 | -$9.39 10-K · filed 2017-03-16 | -$16.50 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$24.54 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$31.45 derived: net income ÷ weighted average shares · filed 2017-03-16 | ||||
| 2014-12-31 | -$7.04 10-K · filed 2016-03-30 | -$14.99 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$21.85 derived: net income ÷ weighted average shares · filed 2017-03-16 | -$29.69 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$8.02 10-K · filed 2016-03-30 | -$14.87 derived: net income ÷ weighted average shares · filed 2015-11-10 | -$22.73 10-Q · filed 2015-11-10 | |||||
| 2014-06-30 | -$6.85 10-K · filed 2016-03-30 | -$14.69 10-Q · filed 2015-08-12 | ||||||
| 2014-03-31 | -$7.87 10-K · filed 2016-03-30 | |||||||
| 2013-12-31 | -$28.39 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |